Aldeyra Therapeutics (ALDX) Tops Q2 EPS by 8c

Aldeyra Therapeutics (NASDAQ: ALDX) reported Q2 EPS of ($0.27), $0.08 better than the analyst estimate of ($0.35).

For earnings history and earnings-related data on Aldeyra Therapeutics (ALDX) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Lennar Corp. (LEN) Misses Q2 EPS by 1c
• Independent Bank receives regulatory approval for HCB Financial acquisition